Los Angeles Capital Management
KRYS icon

Los Angeles Capital Management’s Krystal Biotech KRYS Stock Holding History

Los Angeles Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$561K Hold
2,171
– – ﹤0.01% 839
2025
Q4 		$410K Sell
2,171
-4,586
-68% -$965K ﹤0.01% 973
2025
Q3 		$1.19M Sell
6,757
-19,881
-75% -$2.98M ﹤0.01% 655
2025
Q2 		$3.66M Buy
26,638
+1,709
+7% +$251K 0.01% 352
2025
Q1 		$4.49M Buy
24,929
+15,045
+152% +$2.53M 0.02% 305
2024
Q4 		$1.55M Hold
9,884
– – 0.01% 497
2024
Q3 		$1.8M Sell
9,884
-100
-1% -$19.3K 0.01% 485
2024
Q2 		$1.83M Sell
9,984
-230
-2% -$38.6K 0.01% 477
2024
Q1 		$1.82M Buy
10,214
+629
+7% +$87.4K 0.01% 520
2023
Q4 		$1.19M Sell
9,585
-538
-5% -$59.7K ﹤0.01% 624
2023
Q3 		$1.17M Sell
10,123
-5,839
-37% -$712K 0.01% 585
2023
Q2 		$1.87M Buy
+15,962
New +$1.63M 0.01% 503

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's KRYS Position: Q1 2026 in Review

Los Angeles Capital Management held its Krystal Biotech (KRYS) position steady in Q1 2026 at 2,171 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Los Angeles Capital Management first reported a position in KRYS in Q2 2023 and has held it in 12 quarters since. The position peaked at $4.49M in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Los Angeles Capital Management held 2,171 shares of Krystal Biotech worth $561K as of Q1 2026.
  • Los Angeles Capital Management left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #839 holding.
  • Los Angeles Capital Management first reported a position in Krystal Biotech in Q2 2023 and has held it in 12 quarters since.
  • Los Angeles Capital Management's Krystal Biotech position peaked at $4.49M in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.